Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Both azathioprine and betamethasone treatments effectively regrow hair in alopecia areata, but azathioprine may be safer.

In this study, researchers analyzed social media data to assess the comparative safety of arthritis medications, finding increased odds of herpes zoster and perforated bowel with certain therapies. Social media posts expressed more safety concerns than favorable opinions about drug safety.

This report describes cases of increased hair loss and scalp sunburns in patients using 3% minoxidil and 0.01% tretinoin, suggesting caution with tretinoin use on sunny days.

This case study reports that a pediatric patient with recalcitrant alopecia areata was treated using a 308 nm excimer lamp and topical tofacitinib 2% gel.

This abstract describes the Dermatologic Surgery journal's extensive focus on skin surgery procedures, but it presents no new research findings.

A bald man grew hair on his head after taking a drug called diazoxide, but lost it again when he stopped the medication.

This review discusses the effects of sunlight and artificial UV radiation on the skin and reports no new clinical results; a panel from the NIH found the evidence insufficient to recommend tretinoin for sun-induced wrinkles.

This study reported that etrasimod did not achieve significant improvements in hair regrowth for moderate to severe alopecia areata at 24 weeks, although it showed a dose-dependent trend and was safe and well-tolerated over 52 weeks.

This meeting summary discusses scalp management and the use of topical ketoconazole in therapeutic hair care, but it reports no new research findings.

This study evaluated azathioprine in treating alopecia areata and found that it was effective for 77.4% of patients, significantly reducing SALT scores after 6 months of treatment, with safety monitored through regular testing.

The serum reduces acne and improves skin clarity.

This study found that Ritlecitinib significantly reduced hair loss in patients with alopecia areata by lowering SALT scores at weeks 12 and 24 compared to placebo, with acceptable safety but increased minor side effects like headaches and acne.

This study found that topical γ‐Oryzanol significantly stimulated sebaceous gland cell activity and sebum production in rats.

This article discusses the importance of recognizing adverse drug reactions, methods of prevention, and encourages reporting them to the FDA's MedWatch program; it reports no new results.

This study reviewed clinical trials on JAK inhibitors for alopecia areata, finding them effective for short-term hair regrowth with a favorable safety profile, but noted limited data on long-term risks like malignancies or cardiovascular events beyond two years.

This study developed a new triamcinolone acetonide serum combined with a microneedling device, showing promise for treating alopecia areata by targeting hair follicles in a less invasive, patient-friendly way with confirmed drug solubility, compatibility, and safety.

This study examined 4-azasteroids using 13C-NMR spectroscopy, detailing the NMR spectrum assignments and reporting a new molecular complex of finasteride with dioxane.

This study found that a topical emulsion containing purified extracts of sidr leaves and roasted candlenut seeds significantly increased hair growth compared to the base and 2% minoxidil, potentially through their antioxidant and anti-inflammatory properties.

In this retrospective pharmacovigilance study, researchers analyzed over 7,900 adverse event reports related to aromatase inhibitors, identifying common side effects and toxicological mechanisms to highlight potential safety concerns in treating postmenopausal hormone receptor-positive breast cancer.

In this Italian retrospective study, ritlecitinib 50 mg/day showed effectiveness and good tolerability for treating severe alopecia areata over 24 weeks, achieving significant hair regrowth particularly in adolescents, as well as improvements in eyebrows, eyelashes, nails, and quality of life, with mostly mild adverse effects.

This article compares the efficacy of topical tea and zinc sulfate in treating acne rosacea but does not present new clinical results.

This study reported that ritlecitinib was prescribed to a diverse group of patients with severe alopecia areata in the first 10 months after FDA approval, indicating its potential role in AA management.

This article suggests that a topical sulfonylurea drug may inhibit excessive hair growth caused by diazoxide without affecting its beneficial effects on beta cells, potentially offering a treatment for various forms of hypertrichosis and hirsutism.

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

Deuruxolitinib is generally safe for treating alopecia areata.

This study found that 4-MA is a potent inhibitor of testosterone 5α-reductase in human tissues, promising potential for treating androgen-dependent skin conditions like male pattern baldness.

This study found that econazole nitrate delivered via MPEG-dihexPLA micelles significantly increased skin deposition compared to Pevaryl® cream, potentially enhancing drug bioavailability and clinical efficacy.